tetano
Editor, Senior Moderator
Intest Res
. 2021 Jan 18.
doi: 10.5217/ir.2020.00108. Online ahead of print.
Clinical presentation of COVID-19 in patients with inflammatory bowel disease: a systematic review and meta-analysis
Anupam K Singh[SUP] 1 [/SUP], Anuraag Jena[SUP] 1 [/SUP], Praveen Kumar-M[SUP] 2 [/SUP], Daya Krishna Jha[SUP] 1 [/SUP], Vishal Sharma[SUP] 1 [/SUP]
Affiliations
Abstract
Background/aims: Coronavirus disease 2019 (COVID-19) is recognized to have variable clinical manifestations. The clinical presentation of patients with inflammatory bowel disease (IBD) having COVID-19 is unclear.
Methods: We identified articles reporting about the clinical presentation of COVID-19 in those with underlying IBD from PubMed and Embase. The studies, irrespective of design or language, were included. The overall pooled frequency of various symptoms was estimated. Joanna Briggs Institute Critical appraisal checklist was used to assess the quality of studies.
Results: Eleven studies, including 1,325 patients, were included in the pooled analysis. The pooled estimates for clinical presentation were; fever: 67.53% (95% confidence interval [CI], 45.38-83.88), cough: 59.58% (95% CI, 45.01-72.63), diarrhea: 27.26% (95% CI, 19.51-36.69), running nose: 27% (95% CI, 15.26-43.19) and dyspnea: 25.29% (95% CI, 18.52-33.52). The pooled prevalence rates for abdominal pain, nausea and vomiting were 13.08% (95% CI, 9.24-18.19), 10.08% (95% CI, 5.84-16.85) and 8.80% (95% CI, 4.43-16.70) per 100 population, respectively.
Conclusions: The clinical presentation of COVID-19 in IBD patients is similar to the general population.
Keywords: Coronavirus; Crohn disease; Diarrhea; Inflammatory bowel disease; Ulcerative colitis.
. 2021 Jan 18.
doi: 10.5217/ir.2020.00108. Online ahead of print.
Clinical presentation of COVID-19 in patients with inflammatory bowel disease: a systematic review and meta-analysis
Anupam K Singh[SUP] 1 [/SUP], Anuraag Jena[SUP] 1 [/SUP], Praveen Kumar-M[SUP] 2 [/SUP], Daya Krishna Jha[SUP] 1 [/SUP], Vishal Sharma[SUP] 1 [/SUP]
Affiliations
- PMID: 33440918
- DOI: 10.5217/ir.2020.00108
Abstract
Background/aims: Coronavirus disease 2019 (COVID-19) is recognized to have variable clinical manifestations. The clinical presentation of patients with inflammatory bowel disease (IBD) having COVID-19 is unclear.
Methods: We identified articles reporting about the clinical presentation of COVID-19 in those with underlying IBD from PubMed and Embase. The studies, irrespective of design or language, were included. The overall pooled frequency of various symptoms was estimated. Joanna Briggs Institute Critical appraisal checklist was used to assess the quality of studies.
Results: Eleven studies, including 1,325 patients, were included in the pooled analysis. The pooled estimates for clinical presentation were; fever: 67.53% (95% confidence interval [CI], 45.38-83.88), cough: 59.58% (95% CI, 45.01-72.63), diarrhea: 27.26% (95% CI, 19.51-36.69), running nose: 27% (95% CI, 15.26-43.19) and dyspnea: 25.29% (95% CI, 18.52-33.52). The pooled prevalence rates for abdominal pain, nausea and vomiting were 13.08% (95% CI, 9.24-18.19), 10.08% (95% CI, 5.84-16.85) and 8.80% (95% CI, 4.43-16.70) per 100 population, respectively.
Conclusions: The clinical presentation of COVID-19 in IBD patients is similar to the general population.
Keywords: Coronavirus; Crohn disease; Diarrhea; Inflammatory bowel disease; Ulcerative colitis.